X

Trial Profile

A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Custirsen (Primary) ; Dexamethasone; Docetaxel; Prednisone
Indications Adenocarcinoma; Cancer metastases; Prostate cancer
Focus Registrational; Therapeutic Use
Acronyms SYNERGY
Sponsors Achieve Life Sciences; Teva Pharmaceutical Industries

Most Recent Events

01 Aug 2017 Achieve Life Sciences merged with OncoGenex Pharmaceuticals and the later changed its name to Achieve Life Sciences
06 Jun 2017 Results of post-hoc analysis (n=300) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
07 Mar 2017 Results published in the Lancet Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com